Researcher Profile

Researcher Profile

Douglas Stairs, PhD

Douglas Stairs, PhD

Assistant Professor, Department of Pathology and Laboratory Medicine
Division of Experimental Pathology
Assistant Professor, Department of Pharmacology
Scientific Program:Experimental Therapeutics
dbs18@psu.edu

Research Interests

The worldwide prevalence of esophageal cancer varies greatly, with the highest rates found in Asia. In the United States, the two most common types of esophageal cancers are squamous cell carcinoma (ESCC) and adenocarcinoma (EAC). Since patients are typically diagnosed at a late stage of the disease, overall five-year survival is approximately 18 percent. Given the poor survival rate, the advanced stage of the disease at diagnosis and the increasing frequency of ESCC (worldwide) and EAC (U.S.), it is increasingly important to understand the molecular mechanisms of initiation of these tumors as well as the genes and pathways involved, which is what Dr. Douglas Stairs' work focuses on.

  • Barrett Esophagus
  • Neoplasms
  • Epithelium
  • Human Mammary Glands
  • Breast
  • Down-Regulation
  • Mutation
  • Epidermal Growth Factor Receptor
  • Adenocarcinoma
  • Genes
  • Esophageal Neoplasms
  • Epithelial Cells

Recent Publications

2019

[C@36a5a73f

2018

[C@7de1c910

2017

[C@491eaee2

2016

[C@a64c885
[C@58226f2e

2015

Lehman, HL, Yang, X, Welsh, PA & Stairs, D 2015, 'P120-catenin down-regulation and epidermal growth factor receptor overexpression results in a transformed epithelium that mimics esophageal squamous cell carcinoma', American Journal of Pathology, vol. 185, no. 1, pp. 240-251. https://doi.org/10.1016/j.ajpath.2014.09.008

Clinical Trials Search


Children (age < 18 years)
Adults (age >= 18 years)